{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:23:03Z","timestamp":1793290983646,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1053\/j.ajkd.2026.03.037","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:19:41Z","timestamp":1778739581000},"page":"433-438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Weight Loss\u2013Independent Mechanisms of Kidney Protection With Glucagon-Like Peptide 1 Receptor Agonists and Implications for Clinical Practice"],"prefix":"10.1053","volume":"88","author":[{"given":"Allon N.","family":"Friedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilyas","family":"Oultache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hovey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1053\/j.ajkd.2026.03.037_bib1","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"6","key":"10.1053\/j.ajkd.2026.03.037_bib2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.ajkd.2026.03.037_bib3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.ajkd.2026.03.037_bib4","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2026.03.037_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2026.03.037_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2026.03.037_bib7","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial","volume":"31","author":"Apperloo","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"10.1053\/j.ajkd.2026.03.037_bib8","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/j.jrn.2025.07.004","article-title":"Evaluation and management of obesity in chronic kidney disease","volume":"35","author":"Friedman","year":"2025","journal-title":"J Ren Nutr"},{"issue":"1","key":"10.1053\/j.ajkd.2026.03.037_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100568","article-title":"Prevalence of obesity and CKD among adults in the United States, 2017-2020","volume":"5","author":"Friedman","year":"2023","journal-title":"Kidney Med"},{"issue":"1","key":"10.1053\/j.ajkd.2026.03.037_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2021.12.012","article-title":"Why does obesity cause diabetes?","volume":"34","author":"Klein","year":"2022","journal-title":"Cell Metabolism"},{"issue":"6","key":"10.1053\/j.ajkd.2026.03.037_bib11","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/CIRCRESAHA.116.305697","article-title":"Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms","volume":"116","author":"Hall","year":"2015","journal-title":"Circ Res"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2026.03.037_bib12","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.2337\/db25-1971-LB","article-title":"1971-LB: Impact of semaglutide on kidney, cardiovascular, and mortality outcomes by baseline BMI and weight loss in people with T2D and CKD\u2014data from the FLOW Trial [85th Scientific Session of the American Diabetes Association abstract 1971-LB]","volume":"74","author":"Mann","year":"2025","journal-title":"Diabetes"},{"issue":"6","key":"10.1053\/j.ajkd.2026.03.037_bib13","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/dom.13668","article-title":"Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)","volume":"21","author":"Tuttle","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1053\/j.ajkd.2026.03.037_bib14","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.14443","article-title":"Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis","volume":"23","author":"Mann","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1053\/j.ajkd.2026.03.037_bib15","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"10.1053\/j.ajkd.2026.03.037_bib16","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1210\/en.2017-00564","article-title":"The role of GLP-1 in the metabolic success of bariatric surgery","volume":"158","author":"Hutch","year":"2017","journal-title":"Endocrinology"},{"issue":"6","key":"10.1053\/j.ajkd.2026.03.037_bib17","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.soard.2022.02.006","article-title":"Sleeve gastrectomy in patients with severe obesity and baseline chronic kidney disease improves kidney function independently of weight loss: a propensity score matched analysis","volume":"18","author":"Funes","year":"2022","journal-title":"Surg Obes Relat Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2026.03.037_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000357231","article-title":"Predicting the glomerular filtration rate in bariatric surgery patients","volume":"39","author":"Friedman","year":"2014","journal-title":"Am J Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2026.03.037_bib19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.soard.2020.11.010","article-title":"The relationship between kidney function and body mass index before and after bariatric surgery in patients with chronic kidney disease","volume":"17","author":"Fischer","year":"2021","journal-title":"Surg Obes Relat Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2026.03.037_bib20","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.soard.2019.03.013","article-title":"Metabolic surgery improves renal injury independent of weight loss: a meta-analysis","volume":"15","author":"Scheurlen","year":"2019","journal-title":"Surg Obes Relat Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2026.03.037_bib21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.kint.2023.10.014","article-title":"Anti-obesity pharmacotherapy in adults with chronic kidney disease","volume":"105","author":"Taber-Hight","year":"2024","journal-title":"Kidney Int"},{"issue":"21","key":"10.1053\/j.ajkd.2026.03.037_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194749","article-title":"GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity","volume":"135","author":"Cooper","year":"2025","journal-title":"J Clin Invest"},{"issue":"10 suppl","key":"10.1053\/j.ajkd.2026.03.037_bib23","article-title":"Mechanistic effects of semaglutide on kidney disease in type 2 diabetes: the REMODEL Trial [ASN Kidney Week abstract FR-OR089]","volume":"36","author":"Tuttle","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2026.03.037_bib24","doi-asserted-by":"crossref","first-page":"E1019","DOI":"10.1152\/ajpendo.00195.2019","article-title":"Glucagon-like peptide-1 alleviates diabetic kidney disease through activation of autophagy by regulating AMP-activated protein kinase-mammalian target of rapamycin pathway","volume":"319","author":"Yang","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"10.1053\/j.ajkd.2026.03.037_bib25","first-page":"1789","article-title":"Glucagon-like peptide-1 protects mouse podocytes against high glucose-induced apoptosis, and suppresses reactive oxygen species production and proinflammatory cytokine secretion, through sirtuin 1 activation in vitro","volume":"18","author":"Shi","year":"2018","journal-title":"Mol Med Rep"},{"issue":"11","key":"10.1053\/j.ajkd.2026.03.037_bib26","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3390\/metabo13111121","article-title":"GLP-1 receptor agonist improves mitochondrial energy status and attenuates nephrotoxicity in vivo and in vitro","volume":"13","author":"Wang","year":"2023","journal-title":"Metabolites"},{"key":"10.1053\/j.ajkd.2026.03.037_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113877","article-title":"GLP-1\/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K\/AKT mediated suppression of oxidative stress","volume":"146","author":"Tian","year":"2025","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10.1053\/j.ajkd.2026.03.037_bib28","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes","volume":"54","author":"Kodera","year":"2011","journal-title":"Diabetologia"},{"issue":"4","key":"10.1053\/j.ajkd.2026.03.037_bib29","doi-asserted-by":"crossref","first-page":"R410","DOI":"10.1152\/ajpregu.00083.2024","article-title":"Liraglutide ameliorates inflammation and fibrosis by down-regulating the TLR4\/MyD88\/NF-\u03baB pathway in diabetic kidney disease","volume":"327","author":"Huang","year":"2024","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"3","key":"10.1053\/j.ajkd.2026.03.037_bib30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.mvr.2012.06.008","article-title":"Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A","volume":"84","author":"Ishibashi","year":"2012","journal-title":"Microvasc Res"},{"issue":"9","key":"10.1053\/j.ajkd.2026.03.037_bib31","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.metabol.2011.01.010","article-title":"Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level","volume":"60","author":"Ishibashi","year":"2011","journal-title":"Metabolism"},{"key":"10.1053\/j.ajkd.2026.03.037_bib32","article-title":"Exenatide attenuates obesity-induced mitochondrial dysfunction by activating SIRT1 in renal tubular cells","volume":"12","author":"Wang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1053\/j.ajkd.2026.03.037_bib33","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3892\/ijmm.2014.2052","article-title":"Liraglutide inhibits autophagy and apoptosis induced by high glucose through GLP-1R in renal tubular epithelial cells","volume":"35","author":"Zhao","year":"2015","journal-title":"Int J Mol Med"},{"key":"10.1053\/j.ajkd.2026.03.037_bib34","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bbrc.2023.04.012","article-title":"GLP-1 receptor agonist, liraglutide, protects podocytes from apoptosis in diabetic nephropathy by promoting white fat browning","volume":"664","author":"Wang","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1053\/j.ajkd.2026.03.037_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0084-3","article-title":"Exendin-4 ameliorates high glucose-induced fibrosis by inhibiting the secretion of miR-192 from injured renal tubular epithelial cells","volume":"50","author":"Jia","year":"2018","journal-title":"Exp Mol Med"},{"issue":"14","key":"10.1053\/j.ajkd.2026.03.037_bib36","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1177\/1535370219876531","article-title":"Glucagon-like peptide-1 receptor pathway inhibits extracellular matrix production by mesangial cells through store-operated Ca2+ channel","volume":"244","author":"Huang","year":"2019","journal-title":"Exp Biol Med (Maywood)"},{"issue":"3","key":"10.1053\/j.ajkd.2026.03.037_bib37","doi-asserted-by":"crossref","first-page":"F458","DOI":"10.1152\/ajprenal.00128.2020","article-title":"Liraglutide suppresses production of extracellular matrix proteins and ameliorates renal injury of diabetic nephropathy by enhancing Wnt\/beta-catenin signaling","volume":"319","author":"Huang","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1053\/j.ajkd.2026.03.037_bib38","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2147\/DMSO.S353717","article-title":"Glucagon-like peptide 1 receptor agonist improves renal tubular damage in mice with diabetic kidney disease","volume":"15","author":"Li","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"4","key":"10.1053\/j.ajkd.2026.03.037_bib39","doi-asserted-by":"crossref","first-page":"728","DOI":"10.34067\/KID.0000001067","article-title":"Molecular characterization of the effect of glucagon-like peptide-1 receptor agonist semaglutide in the nephrotoxic serum nephritis mouse model","volume":"7","author":"Martinez","year":"2025","journal-title":"Kidney360"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626008875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626008875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T08:42:21Z","timestamp":1787215341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638626008875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0272638626008875"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.03.037","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Weight Loss\u2013Independent Mechanisms of Kidney Protection With Glucagon-Like Peptide 1 Receptor Agonists and Implications for Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.03.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}